Placebo vs Amoxicillin for Nonsevere Fast-Breathing Pneumonia in Malawian Children Aged 2 to 59 Months
Open Access
- 1 January 2019
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Pediatrics
- Vol. 173 (1) , 21-28
Abstract
Approximately 920 000 children die of pneumonia annually before their fifth birthday.1 There is a critical need to provide greater access to appropriate and effective treatment. Treatment of bacterial pneumonia requires an effective antibiotic used in adequate doses for an appropriate duration. A 3-day course of twice-daily amoxicillin is recommended by the World Health Organization (WHO) as first-line treatment of nonsevere fast-breathing pneumonia among immune-competent children aged 5 years or less.2 The WHO’s integrated management of childhood illness (IMCI) guidelines identify fast-breathing pneumonia in children with cough or difficult breathing who demonstrate fast breathing without WHO danger signs.3 However, not all cases of fast breathing are bacterial pneumonia. Indeed, the majority of fast-breathing pneumonia cases are likely not pneumonia at all. There are many reasons that a child might demonstrate fast breathing, and not all indicate disease.4-7 Thus, isolated fast breathing may not be appropriately sensitive nor specific for diagnosing pneumonia,8 making antibiotic treatment unnecessary. Although it is relatively well tolerated among children, amoxicillin has side effects and causes serious but rare adverse events.9 Furthermore, inappropriate antibiotic use may lead to antibiotic resistance.10-15Keywords
This publication has 27 references indexed in Scilit:
- Bacterial infections in Lilongwe, Malawi: aetiology and antibiotic resistanceBMC Infectious Diseases, 2012
- The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2011
- Comparison of Oral Amoxicillin with Placebo for the Treatment of World Health Organization-Defined Nonsevere Pneumonia in Children Aged 2-59 Months: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial in PakistanClinical Infectious Diseases, 2010
- A Review of Hot Deck Imputation for Survey Non‐responseInternational Statistical Review, 2010
- Chest radiography in children aged 2-59 months diagnosed with non-severe pneumonia as defined by World Health Organization: descriptive multicentre study in PakistanBMJ, 2006
- Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controlled trialBMJ, 2004
- The Importance of the Normality Assumption in Large Public Health Data SetsAnnual Review of Public Health, 2002
- The Crisis in Antibiotic ResistanceScience, 1992
- Standardized diagnosis of pneumonia in developing countriesThe Pediatric Infectious Disease Journal, 1992
- Maximum Likelihood Estimation of Misspecified ModelsEconometrica, 1982